A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Sotatercept (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacokinetics
- Acronyms LIGHTRAY
- Sponsors Merck Sharp & Dohme
- 19 Nov 2024 Status changed from not yet recruiting to recruiting.
- 06 Nov 2024 New trial record